GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AVEO Pharmaceuticals Inc (STU:VPA1) » Definitions » Cyclically Adjusted PS Ratio

AVEO Pharmaceuticals (STU:VPA1) Cyclically Adjusted PS Ratio : (As of Jun. 06, 2024)


View and export this data going back to 2013. Start your Free Trial

What is AVEO Pharmaceuticals Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


AVEO Pharmaceuticals Cyclically Adjusted PS Ratio Historical Data

The historical data trend for AVEO Pharmaceuticals's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AVEO Pharmaceuticals Cyclically Adjusted PS Ratio Chart

AVEO Pharmaceuticals Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

AVEO Pharmaceuticals Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of AVEO Pharmaceuticals's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, AVEO Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AVEO Pharmaceuticals's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AVEO Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where AVEO Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.



AVEO Pharmaceuticals Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

AVEO Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2022 is calculated as:

For example, AVEO Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Sep. 2022 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Sep. 2022 (Change)*Current CPI (Sep. 2022)
=0.888/125.2265*125.2265
=0.888

Current CPI (Sep. 2022) = 125.2265.

AVEO Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201212 2.721 96.871 3.517
201303 0.050 98.209 0.064
201306 0.048 98.518 0.061
201309 0.047 98.790 0.060
201312 0.046 98.326 0.059
201403 2.141 99.695 2.689
201406 0.263 100.560 0.328
201409 0.131 100.428 0.163
201412 0.017 99.070 0.021
201503 0.024 99.621 0.030
201506 0.022 100.684 0.027
201509 2.369 100.392 2.955
201512 0.568 99.792 0.713
201603 0.186 100.470 0.232
201606 0.026 101.688 0.032
201609 0.117 101.861 0.144
201612 0.016 101.863 0.020
201703 0.310 102.862 0.377
201706 0.028 103.349 0.034
201709 0.328 104.136 0.394
201712 0.006 104.011 0.007
201803 0.070 105.290 0.083
201806 0.029 106.317 0.034
201809 0.176 106.507 0.207
201812 0.079 105.998 0.093
201903 0.107 107.251 0.125
201906 0.039 108.070 0.045
201909 1.452 108.329 1.678
201912 0.043 108.420 0.050
202003 0.044 108.902 0.051
202006 0.038 108.767 0.044
202009 0.118 109.815 0.135
202012 0.028 109.897 0.032
202103 0.059 111.754 0.066
202106 0.182 114.631 0.199
202109 0.375 115.734 0.406
202112 0.454 117.630 0.483
202203 0.551 121.301 0.569
202206 0.694 125.017 0.695
202209 0.888 125.227 0.888

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


AVEO Pharmaceuticals  (STU:VPA1) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


AVEO Pharmaceuticals Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of AVEO Pharmaceuticals's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


AVEO Pharmaceuticals (STU:VPA1) Business Description

Traded in Other Exchanges
N/A
Address
30 Winter Street, Boston, MA, USA, 02108
AVEO Pharmaceuticals Inc is a commercial-stage, oncology-focused biopharmaceutical company engaged in offering medicines that provide a better life for patients with cancer. The company markets FOTIVDA (tivozanib) in the United States. FOTIVDA is an oral, next-generation vascular endothelial growth factor receptor, or VEGFR, tyrosine kinase inhibitor, or TKI. The group primarily operates in the U.S.

AVEO Pharmaceuticals (STU:VPA1) Headlines

No Headlines